摘要
目的观察分析利奈唑胺治疗重症监护病房感染患者的临床疗效和安全性。方法回顾性分析2007年6月-2009年2月在医院重症监护病房收治的31例患者,根据细菌培养结果或临床经验性给予利奈唑胺治疗,分析评价临床疗效。结果 31例患者痊愈患者9例(29.0%),显效患者16例(51.6%),进步患者4例(12.9%),无效患者2例(6.5%),总体临床有效率80.6%,在不同基础疾病、感染部位中治愈率差异无统计学意义;临床改善情况总体有效率79.6%,细菌清除率93.9%,总体临床有效率80.6%。结论利奈唑胺治疗重症监护病房革兰阳性菌感染安全性好,临床疗效卓越。
OBJECTIVE To observe and analyze the clinical efficacy and safety of linezolid in the treatment of infection in the intensive care unit.METHODS A retrospective analysis of the 31 cases in ICU with infection was enrolled in our hospital from Jun 2006 to Feb 2009 who were treated with linezolid according to the bacterial culture results or clinical experience,and the clinical efficacy was evaluated.RESULTS Among the 31 cases,9 cases cured（29%）,16 cases had positive response（51.6%）,4 cases improved（12.9%）,and 2 cases had no efficacy（6.5%）,the overall effective rate was 80.6%,and there was no significant statistical difference in the clinical cure rate among the cases with different underlying diseases and infection sites.The overall clinical improvement rate was 79.6%,the bacterial clearance rate was 93.9% and the overall effective rate was 80.6%.CONCLUSIONS Linezolid has high safety and exellent clincial efficacy in the treatment of Gram-positive bacteria infection in ICU.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2010年第14期2116-2118,共3页
Chinese Journal of Nosocomiology
